Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule dipeptide derivative containing a boronic acid moiety. It is structurally characterized as a peptidomimetic with the formula C23H27BN4O4 and has been referenced in chemical and structural databases under the code names PPB and DB08420. The compound has not been approved for any therapeutic use, nor does it have any known clinical indications or ongoing clinical trials. Its mechanism of action, biological targets, or pharmacological activity are not described in public drug databases, suggesting it remains an experimental research molecule without established pharmaceutical application[3][6][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-{[1-(2-amino-3-phenyl-propionyl)-pyrrolidine-2-carbonyl]-amino}-2-(3-cyano-phenyl)-ethaneboronic acid.